Glaxosmithkline

Ligand, Glaxo drug gets European approval SAN DIEGO ? Ligand Pharmaceuticals Inc. said Friday that partner GlaxoSmithKline gained European regulatory approval to sell the blood disorder drug Revolade. In December, a European advisory committee recommended approving the drug. It was discovered by... by blog.taragana.com | related posts

Nabi closes license deal with GlaxoSmithKline ROCKVILLE, Md. ? Nabi Pharmaceuticals said Monday it closed an option and license agreement for the smoking vaccine candidate NicVAx with GlaxoSmithKline. The deal is potentially worth more than $500 million, including a $40 million... by blog.taragana.com | related posts

Following drug maker, GlaxoSmithKline’s, announcement last month that it is no longer making, distributing, or issuing advertisements for its Super Poligrip with zinc, a recall has been issued in Japan, said WFAA. Now, many are wondering why a similar recall is not taking place in the United... by newsinferno.com | related posts

Nabi shareholders approve deal with Glaxo ROCKVILLE, Md. ? Nabi Biopharmaceuticals said Tuesday shareholders approved its option and license agreement for the smoking vaccine candidate NicVAx with GlaxoSmithKline. More than 73 percent of Nabi’s outstanding shares were voted in favor of the... by blog.taragana.com | related posts

Senate report: Avandia maker knew of cardiac risks NEW YORK ? A Senate report said Saturday that drug maker GlaxoSmithKline knew of possible heart attack risks tied to Avandia, its diabetes medication, years before such evidence became public. Sen. Max Baucus, chairman of the Senate Finance... by blog.taragana.com | related posts

regard for the phases of the business cycle. But beneath this healthy-looking exterior, a malignancy has been spreading through Big Pharma's body corporate. The business model that helped create some of the highest-earning firms of modern times - names such as Pfizer in the US, Bayer in Germany, and... by pharmagossip.blogspot.com | related posts

GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (Nasdaq:XNPT) Wednesday received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant™ (gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic... by medicalnewstoday.com | related posts

Regulus and Glaxo will work on hepatitis C drugs NEW YORK ? Drugmaker Regulus Therapeutics LLC said Thursday it is expanding a partnership with GlaxoSmithKline, and will begin researching new treatments for hepatitis C. Regulus said it will identify a potential drug candidate in late 2010, and... by blog.taragana.com | related posts

more images more images Regulus and Glaxo will work on hepatitis C drugs NEW YORK ? Drugmaker Regulus Therapeutics LLC said Thursday it is expanding a partnership with GlaxoSmithKline, and will begin researching new treatments for hepatitis C. Regulus said it will identify a potential drug... by blog.taragana.com | related posts

GlaxoSmithKline is defending its controversial diabetes drug, Avandia, following the release of a Senate Finance Committee report that charged the drug maker downplayed the drug’s heart risks. According to The Associated Press, in a 30-page “white paper”, Glaxo claims the Senate report... by newsinferno.com | related posts